

COMMERCE Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/517,979	12/19/2005	Varghese John	02-414-A1	1935
20306 7590 12/28/2007 MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP		EXAMINER		
300 S. WACKER DRIVE			JAVANMARD, SAHAR	
32ND FLOOR CHICAGO, IL			ART UNIT PAPER NUMBER	
011107100, 12			1617	
			·	
			MAIL DATE	DELIVERY MODE
			12/28/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

•						
	Application No.	Applicant(s)				
	10/517,979	JOHN ET AL.				
Office Action Summary	Examiner	Art Unit				
·	SAHAR JAVANMARD	1617				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	correspondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period way reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tir vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N				
Status						
·— ·	Responsive to communication(s) filed on <u>13 December 2004</u> .					
/-	,					
•—) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
closed in accordance with the practice under E	x parte Quayle, 1955 C.D. 11, 4	03 O.G. 213.				
Disposition of Claims						
4) Claim(s) 1-7,23-25 and 27 is/are pending in the 4a) Of the above claim(s) is/are withdray 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1-7,23-25 and 27 are subject to restrict	vn from consideration.					
Application Papers						
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) acc Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Ex	epted or b) objected to by the drawing(s) be held in abeyance. Se tion is required if the drawing(s) is ob	e 37 CFR 1.85(a). ojected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summar Paper No(s)/Mail D 5) Notice of Informal 6) Other:	Date				

10/517,979 Art Unit: 1617

DETAILED ACTION

Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The inventions listed below do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical feature for the following reasons: the compounds employed are already known in the prior art and each formulation comprises compounds having different variable core structures and corresponding functionalities.

Specifically, Göschke et al. (US 5,606,078) discloses the synthesis of aryl alkanoic acid amide compounds of formula I (column 5, lines 39-50, structure IIc).

In conclusion, there is a lack of unity of invention, and therefore restriction for examination purposes is proper.

Election

This application contains claims directed to more than one species of drug/active agent of the generic invention. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species of each genus compound claimed for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. For example, applicant is required to define each of R1, R2, and R3 and any additional

Application/Control Number:

10/517,979 Art Unit: 1617

variables as required for the particular species of the compound in claim 1. Applicant is further required to elect a species as shown below:

1) a disease (such as from the list in claim 1)

Currently claims 1-7 are generic.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

It is considered that at Markush type claim encompassing such species is directed to multiple independent and patentably distinct inventions since the species are so unrelated and diverse that a prior art reference anticipating the claims with respect to one of the species will not render the claim anticipated or obvious under 35 U.S.C. 102 nor 35 U.S.C. 103 respectively with regard to any one other of the species. Further these species are considered to be independent since they are unconnected in operation, one does not require the others for ultimate use and the specification does not disclose a dependent relationship between them. Moreover, each of the stated species is considered patentably distinct from the others on the basis of its properties. Thus, the stated species are capable of supporting separate patents under 35 U.S.C. 121.

Accordingly, <u>applicants are required</u> to make a provisional election of a single independent and/or patentably distinct Invention stated supra prior to an examination of

Application/Control Number:

10/517.979

Art Unit: 1617

said species on the merits. This election will be given effect in the event the Markush type claims are not found allowable, at which time the examination of the claims presented will be limited to the Markush type claims and claims directed solely to the elected species. The claims directed solely to the nonelected species will be held withdrawn from further consideration. It should be noted that an election of species has been held to be tantamount to a requirement for restriction (see In re Herrick, 1958 CD 1, and *In re Joyce* 1958 CD2).

Applicant's response must include a provisional election of one of the independent and patentably distinct inventions identified above even though the requirement is traversed (37 C.F.R. 1.142 and 1.143). Applicant is advised that any traverse must be supported by argument in order to perfect the right to petition in the event that the provisional requirement is given effect in the event noted above.

Inventorship Notice

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

10/517,979 Art Unit: 1617

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to SAHAR JAVANMARD whose telephone number is (571) 270-3280. The examiner can normally be reached on 8 AM-5 PM MON-FRI (EST).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Sus

SREENI PADMANABHAN SUPERVISORY PATENT EXAMINER